Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | NMT2 | O60551 | 1/20 | 0.47 |
| ▸ | NMT1 | P30419 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.40 |
| ▸ | FURIN | P09958 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1573989 | 1.00 | NOD1 (0.58) | NOD1FOLH1NMT2NMT1SLC6A5 | |
| SCHEMBL30985184 | 0.98 | NOD1 (0.60) | NOD1FOLH1NMT2NMT1SLC6A5 | |
| SCHEMBL6129561 | 0.93 | NOD1 (0.61) | NOD1FOLH1NMT2NMT1SLC6A5 | |
| SCHEMBL2508780 | 0.93 | NOD1 (0.61) | NOD1FOLH1NMT2NMT1SLC6A5 | |
| SCHEMBL20529374 | 0.90 | NMT2 (0.43) | NOD1FOLH1NMT2NMT1CPB2 | |
| SCHEMBL21330513 | 0.90 | NOD1 (0.68) | NOD1FOLH1NMT2NMT1SLC6A5 | |
| SCHEMBL2512125 | 0.89 | FOLH1 (0.53) | NOD1FOLH1NMT2NMT1CPB2 | |
| SCHEMBL30512604 | 0.89 | FOLH1 (0.53) | NOD1FOLH1NMT2NMT1CPB2 | |
| SCHEMBL29451703 | 0.89 | FOLH1 (0.60) | NOD1FOLH1NMT2NMT1SLC6A5 | |
| SCHEMBL29451463 | 0.89 | FOLH1 (0.60) | NOD1FOLH1NMT2NMT1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250354192-A1 | METHODS FOR QUANTIFYING LIVE BACTERIA | ANCERA INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250288640-A1 | GLYCOPEPTIDE COMPOSITIONS | HIKMA PHARMACEUTICALS USA INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-12343373-B2 | Glycopeptide antibiotics liquid formulations and methods and uses thereof | SOMERSET THERAPEUTICS, LLC (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4540404-A1 | METHODS FOR QUANTIFYING LIVE BACTERIA | Ancera Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12161690-B2 | Glycopeptide compositions | HIKMA PHARMACEUTICALS USA INC. (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2023245172-A1 | METHODS FOR QUANTIFYING LIVE BACTERIA | ANCERA INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20230355520-A1 | METHODS AND COMPOSITIONS FOR TREATING DIABETIC FOOT ULCERS | PATHWAY DEV LLC (US) | 2023-11-09 | — | — | US | disclosed |
| US-11707433-B2 | Methods and compositions for treating diabetic foot ulcers | PATHWAY DEVELOPMENT LLC (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230158101-A1 | GLYCOPEPTIDE COMPOSITIONS | HIKMA PHARMACEUTICALS USA INC. | 2023-05-25 | — | — | US | disclosed |
| US-11628200-B2 | Glycopeptide compositions | XELLIA PHARMACEUTICALS APS (DK) | 2023-04-18 | — | — | US | disclosed |
| EP-4147710-A1 | GLYCOPEPTIDE COMPOSITIONS IN SOLUTION | Xellia Pharmaceuticals ApS (DK) | 2023-03-15 | — | — | EP | disclosed |
| US-11517609-B2 | Glycopeptide compositions | XELLIA PHARMACEUTICALS APS (DK) | 2022-12-06 | — | — | US | disclosed |
| US-20220354927-A1 | Glycopeptide Compositions | XELLIA PHARMACEUTICALS APS (DK) | 2022-11-10 | — | — | US | disclosed |
| US-11433115-B2 | Glycopeptide antibiotics liquid formulations and methods and uses thereof | SOMERSET THERAPEUTICS, LLC (US) | 2022-09-06 | — | — | US | disclosed |
| CN-111826389-B | Method for improving extracellular secretion level of escherichia coli recombinant protein | 江南大学 | 2022-05-13 | — | — | CN | disclosed |
| US-20220133845-A1 | GLYCOPEPTIDE ANTIBIOTICS LIQUID FORMULATIONS AND METHODS AND USES THEREOF | SOMERSET THERAPEUTICS, LLC (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220133844-A1 | GLYCOPEPTIDE ANTIBIOTICS LIQUID FORMULATIONS AND METHODS AND USES THEREOF | SOMERSET THERAPEUTICS, LLC (US) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12343373-B2 | Glycopeptide antibiotics liquid formulations and methods and uses thereof | ALB, ASNS, PTMS | NOD1 513/4885FOLH1 313/4885NMT2 146/4885 |
| US-20230355520-A1 | METHODS AND COMPOSITIONS FOR TREATING DIABETIC FOOT ULCERS | PIK3C3, POLR1C, SLC5A2 | NOD1 100/4885FOLH1 3740/4885NMT2 2865/4885 |
| US-11517609-B2 | Glycopeptide compositions | ASNS, B3GNT2, OGT | NOD1 1525/4885FOLH1 888/4885NMT2 88/4885 |
| US-20220133844-A1 | GLYCOPEPTIDE ANTIBIOTICS LIQUID FORMULATIONS AND METHODS AND USES THEREOF | ALB, ASNS, PTMS | NOD1 513/4885FOLH1 313/4885NMT2 146/4885 |
| US-20220133845-A1 | GLYCOPEPTIDE ANTIBIOTICS LIQUID FORMULATIONS AND METHODS AND USES THEREOF | ALB, ASNS, PTMS | NOD1 513/4885FOLH1 313/4885NMT2 146/4885 |
| US-20220354927-A1 | Glycopeptide Compositions | ASNS, B3GNT2, OGT | NOD1 1525/4885FOLH1 888/4885NMT2 88/4885 |
| US-20250288640-A1 | GLYCOPEPTIDE COMPOSITIONS | ASNS, OGT, B3GNT2 | NOD1 1726/4885FOLH1 1048/4885NMT2 80/4885 |
| US-20230158101-A1 | GLYCOPEPTIDE COMPOSITIONS | ASNS, OGT, B3GNT2 | NOD1 1726/4885FOLH1 1048/4885NMT2 80/4885 |
| US-12161690-B2 | Glycopeptide compositions | ASNS, OGT, B3GNT2 | NOD1 1726/4885FOLH1 1048/4885NMT2 80/4885 |
| US-11628200-B2 | Glycopeptide compositions | ASNS, B3GNT2, OGT | NOD1 1525/4885FOLH1 888/4885NMT2 88/4885 |
| US-11707433-B2 | Methods and compositions for treating diabetic foot ulcers | PIK3C3, POLR1C, SLC5A2 | NOD1 100/4885FOLH1 3740/4885NMT2 2865/4885 |
| US-11433115-B2 | Glycopeptide antibiotics liquid formulations and methods and uses thereof | ALB, ASNS, PTMS | NOD1 513/4885FOLH1 313/4885NMT2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.